Variants are globally emerging very quickly following pandemic prototypic SARS-CoV-2.To evaluate the cross-protection of prototypic SARS-CoV-2 vaccine against its variants,we vaccinated rhesus monkeys with three doses...Variants are globally emerging very quickly following pandemic prototypic SARS-CoV-2.To evaluate the cross-protection of prototypic SARS-CoV-2 vaccine against its variants,we vaccinated rhesus monkeys with three doses of prototypic SARS-CoV-2 inactivated vaccine,followed by challenging with emerging SARS-CoV-2 variants of concern(VOCs).展开更多
基金This study was supported by the National Key R&D Project of China(2021YFC230170402,2021YFC0863300,2020YFC0846400,2020YFA0707602)Kunming Science and Technology Project(2020-1-11-021)+1 种基金CAMS Innovation Fund for Medical Sciences(2021-1-I2M-038,and 2020-I2M-COV19-012)Yunnan Key R&D Project(202003AC100003,202103AQ100001).
文摘Variants are globally emerging very quickly following pandemic prototypic SARS-CoV-2.To evaluate the cross-protection of prototypic SARS-CoV-2 vaccine against its variants,we vaccinated rhesus monkeys with three doses of prototypic SARS-CoV-2 inactivated vaccine,followed by challenging with emerging SARS-CoV-2 variants of concern(VOCs).
